Erratum for Armstrong et al., J Clin Oncol 25 (25) 3965-3970.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

ERRATA

In the Discussion section, the third sentence of the first paragraph gave the PSA level of decline as 67% for patients receiving every-3-weeks docetaxel regimen, while it should have been 65%, as follows:

"In these trials, this level of decline paralleled the effects of treatment; in TAX327, 65% of patients receiving every-3-weeks docetaxel regimen achieved this level of decline as compared with 44% of patients receiving every-3-weeks mitoxantrone, while in the SWOG 9916 trial, the proportions of patients achieving a 30% PSA decline were 76% and 40%, respectively.³"

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content